Wave Life Sciences Ltd.
Wave Life Sciences Announces Pricing of $200 Million Public Offering
Summary
Wave Life Sciences Ltd. has announced the pricing of its upsized public offering of ordinary shares and pre-funded warrants, expected to close on September 27, 2024. The offering, which includes 23,125,001 ordinary shares priced at $8.00 each and pre-funded warrants to purchase up to 1,875,023 ordinary shares at $7.9999 each, is expected to generate approximately $200 million in gross proceeds before underwriting discounts and commissions. The underwriters have an option to purchase up to an additional 3,750,000 ordinary shares. Wave Life Sciences expects its cash runway to extend into 2027 with these proceeds, excluding potential milestone payments under its GSK and Takeda collaborations.
Get alerts for WVE
Be first to know when Wave Life Sciences Ltd. files with the SEC.
Filing Categories
Exhibits (5)
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd. is a biotechnology company engaged in the research and development of stereopure nucleic acid therapies. The primary focus of Wave Life Sciences is to leverage its unique platform to design and optimize therapies that modulate RNA to address genetic diseases. This involves developing treatments with high specificity and efficacy, potentially offering advantages over traditional nucleic acid therapies. The company targets a range of serious diseases, including those related to the central nervous system, with its innovative therapies. Wave Life Sciences plays a significant role in the biopharmaceutical industry by expanding the potential of gene medicine. Its work has implications for sectors such as healthcare and pharmaceuticals, especially in developing new treatment modalities for unmet medical needs. The company's research and development efforts are geared towards delivering transformational outcomes for patients, positioning it as a pioneer in the evolving field of genetic medicine. Wave Life Sciences Ltd. claims a critical space within the market for its advancements in precision medicine and continues to collaborate with various stakeholders to push the boundaries of therapeutic development.
Official SEC Documents